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A B S T R A C T
Objective: Current research does not provide a clear explanation for why some
patients with Parkinson’s Disease (PD) develop psychotic symptoms. The ‘aberrant salience hypothesis’ of psychosis has been influential and proposes that dopa-
minergic dysregulation leads to inappropriate attribution of salience to irrelevant/non-informative stimuli, facilitating the formation of hallucinations and delusions.
The aim of this study is to investigate whether non-motivational salience is altered in PD patients and possibly linked to the development of psychotic symptoms.
Methods: We investigated salience processing in 14 PD patients with psychotic symptoms, 23 PD patients without psychotic symptoms and 19 healthy controls. All
patients were on dopaminergic medication for their PD. We examined emotional salience using a visual oddball fMRI paradigm that has been used to investigate early
stages of schizophrenia spectrum psychosis, controlling for resting cerebral blood flow as assessed with arterial spin labelling fMRI.
Results: We found significant differences between patient groups in brain responses to emotional salience. PD patients with psychotic symptoms had enhanced brain
responses in the striatum, dopaminergic midbrain, hippocampus and amygdala compared to patients without psychotic symptoms. PD patients with psychotic
symptoms showed significant correlations between the levels of dopaminergic drugs they were taking and BOLD signalling, as well as psychotic symptom scores.
Conclusion: Our study suggests that enhanced signalling in the striatum, dopaminergic midbrain, the hippocampus and amygdala is associated with the development
of psychotic symptoms in PD, in line with that proposed in the ‘aberrant salience hypothesis’ of psychosis in schizophrenia.
1. Introduction
Parkinson’s disease (PD) patients frequently suffer from psychotic
symptoms which most commonly takes the form of visual hallucina-
tions, delusions and illusions (Aarsland et al., 1999). With disease
progression psychotic symptoms may shift to other modalities such as
the auditory domain, comprising auditory hallucinations of in-
comprehensible voices (Inzelberg et al., 1998) or non-verbal sounds
(Fenelon, 2000). PD psychosis characterises a spectrum of such
psychotic symptoms that occur throughout the course of the disease,
but especially in those with longer disease duration, higher age and
possibly higher doses of, or certain kinds of, dopaminergic medication,
giving an overall prevalence of 26% (Forsaa et al., 2010; Gibson et al.,
2013; Mack et al., 2012). Subsequently, risk and modulatory factors
include genetics, the use of dopamine-based antiparkinsonian drugs,
and disease-specific factors such as cognitive impairment, dementia,
duration and severity of PD, depression, sleep disorders, along with age
and the presence of intercurrent infections or illnesses (Fénelon and
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Alves, 2010; Friedman, 2010; Morgante et al., 2012). Its development is
associated with increased risk for mortality and nursing home place-
ment as well as lower overall global functioning and well-being
(Ffytche et al., 2017).
Current research suggests that PD psychosis combines a set of
symptoms with a specific pathophysiology (comprehensive review
(Ffytche et al., 2017)), rather than a single mechanistic dysfunction.
Although there are clear differences between the primary psychiatric
disorder of (schizophrenia spectrum) psychosis and PD psychosis, a
disturbed dopaminergic system is a unifying element in both diseases,
possibly contributing to the occurrence of psychotic symptoms in both
disorders (Carter and Ffytche, 2015; Garofalo et al, 2017). PD psychosis
is particularly interesting as it is commonly found as a comorbidity in
PD patients but does not affect all.
A dysfunctional dopaminergic signal, perhaps in the mesolimbic
regions, is argued to be associated with the inappropriate attribution of
salience to otherwise irrelevant or non-informative stimuli, allowing for
the formation of hallucinations and delusions; this theory has been
termed the ‘aberrant salience hypothesis’ of psychosis (Heinz, 2002;
Kapur, 2003; Roiser et al., 2013). Some models propose that within the
hippocampal-striatal-midbrain circuits, hippocampal dysfunction leads
to an enhanced subcortical dopaminergic signalling through descending
projections to the ventral striatum (Lisman and Grace, 2005; Lodge and
Grace, 2007). Supporting the involvement of these circuits, a recent
study investigating novelty salience processing reported increased
connectivity of hippocampal to striatal and midbrain regions, but de-
creased connectivity between the striatum and the midbrain in subjects
at high risk of developing psychosis (Modinos et al., 2019). Further-
more, our previous work in first-episode psychosis patients, using the
same salience paradigm as Modinos et al (2019), showed reduced
midbrain, striatal and occipital activation while processing novelty and
negative emotional salient stimuli (Knolle et al., 2018). In Parkinson’s
disease research, a previous study showed that the use of a dopamine
agonist (pramipexole or ropinirole) in young, medication-naïve PD
patients led to an increase in aberrant motivational salience by facil-
itating arbitrary and illusory associations between stimuli and rewards
with faster reaction times to task-irrelevant stimuli (Nagy et al., 2012).
Unmedicated patients in that latter study did not suffer from psychotic
symptoms, but had increased subscales on the O-LIFE unusual experi-
ence score after treatment with dopaminergic agents (Nagy et al.,
2012). The authors suggest that the dopamine-agonist therapy to treat
Parkinsonian symptoms might give rise to psychotic symptoms as the
disorder progresses. Furthermore, another study (Mannan et al., 2008)
suggested impaired salience processing in PD: in an eye-gaze experi-
ment, patients showed an impaired ability to detect a salient stimulus in
a visual search task. No psychotic symptoms were reported for the
patients in that latter study. In our previous work (Garofalo et al.,
2017), we investigated reward processing, a form of motivation sal-
ience, in PD patients with and without psychotic symptoms and in
controls. PD patients with psychotic symptoms showed very similar
patterns of reduced activation (including in the striatum and cingulate
cortex) as reported in primary psychosis individuals (Ermakova et al.,
2018; Murray et al., 2008).
In the current study, we sought to explore whether the ‘aberrant
salience hypothesis’ of psychosis can be applied to psychosis seen in PD,
affecting not only reward based salience (Garofalo et al., 2017), but also
non-motivational salience. By so doing we sought to provide an ex-
planation as to how psychotic symptoms arise in PD patients (Poletti,
2018). To our knowledge, the current study is the first to investigate
brain responses to non-motivational salient visual stimuli in patients
with and without PD psychotic symptoms. The comparison between the
two patient groups is our main focus in this study. Additionally, we
tested healthy controls. We used an fMRI salience paradigm (Bunzeck
and Düzel, 2006) that previously has shown significantly altered mid-
brain, striatal, hippocampal and amygdala activations and connectivity
in early stages of “psychiatric” psychosis in young adults (Knolle et al.,
2018; Modinos et al., 2019).
This salience paradigm designed by Bunzeck and Düzel (2006)
provides a multidimensional approach to salience, with four types of
salient oddballs. As outlined in the orignial study four different types of
salience (i.e., novelty, emotional salience, rareness and targetness) can
be investigated. Rareness, however, is a frequency oddball generated
using the contrast of the neutral oddball minus neutral standard, these
two stimuli only vary in frequency but not in content. The other sal-
ience types (i.e., negative emotional salience, novelty, targetness) are
differ in content and are matched in frequency, due to being generated
from a contrast with the neutral oddball. (i.e., novelty – neutral, emo-
tional – neutral, targetness – neutral). In this study, we concentrated on
negative emotional salience for two reasons. First, PD shows a pro-
gressive and chronic degeneration of the nigrostriatal and mesocorti-
colimbic dopaminergic systems (Braak et al., 2005; Wu et al., 2012) and
an impaired dopaminergic pathway of emotional processing
(Badgaiyan, 2010; Laviolette, 2007; Salgado-Pineda et al., 2005). PD
patients therefore show a wide range of emotional processing deficits
(see recent reviews: (Moonen et al., 2017; Péron et al., 2012)), mainly
linked to n abnormalities in predominantly ventral regions of the af-
fective neurocircuitry. Second, in our recent study using the same
paradigm in patients with an early psychosis, we found the strongest
and most robust effect to be in emotional salience (Knolle et al., 2018).
Based on the literature of deficits in emotional processing in PD and our
previous findings, we hypothesised, first, that PD psychosis patients
would demonstrate altered negative emotional salience brain responses
in the ventral dopaminergic midbrain (i.e. substantia nigra/VTA),
striatum, hippocampus and amygdala compared to healthy controls
and, second, that PD patients without psychotic symptoms would show
intermediate processing in response to negative emotional salience
compared to healthy controls and PD patients with psychotic symp-
toms.
The aberrant salience theory of psychosis has posited that whilst
perceptual salience may be misattributed in psychosis, higher-order
cognitive processes are invoked to shape abnormal experiences into
abnormal beliefs. Whilst our focus in the current study is on brain
correlates of emotional salience processing, in a preliminary analysis
we also examined whether higher-order (probabilistic) reasoning is
affected in PD psychosis.
2. Methods
2.1. Subjects
In total, we recruited 26 participants, who had a diagnosis of PD
without any psychotic symptoms using established diagnostic criteria;
15 participants with a diagnosis of PD and ongoing or previous psy-
chotic symptoms, and 19 healthy control subjects, without any history
of neurological or psychiatric disorder, matched for age, gender and
education (see Table 1). We assessed psychotic symptoms in Parkinson’s
patients using the Comprehensive Assessment of At Risk Mental States
(CAARMS) (Yung et al., 2005) as well as the Positive and Negative
Symptom Scale (PANSS) (Kay et al., 1987) – also see our previous work
(Garofalo et al., 2017) for a detailed description) and Table 1. For two
participants, one healthy control and one PD patient with psychotic
symptoms, the fMRI session had to be aborted during scanning of the
relevant task, as both participants felt uncomfortable inside the
scanner. Both participants decided not to continue with the scanning
and so were excluded from any analysis. Additionally, two PD patients
without psychotic symptoms were excluded due to excessive movement
artefact in the scanner (see details below). Finally, two outliers were
identified during our analysis, one healthy control and one PD patient
without psychotic symptoms, who exceeded -/+ two standard devia-
tions from the averaged imaging signal in all regions of interest (ROI).
The final sample therefore comprised of 52 participants: 23 PD patients
without psychotic symptoms, 17 healthy controls and 14 PD patients
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with psychotic symptoms.
Patients were recruited via the PD research clinic at the John van
Geest Centre for Brain Repair (VGB). All patients met Queen Square
Brain Bank Criteria for idiopathic PD (Gibb and Lees, 1988) and the
patients remained on their usual medications during testing. Patients
with dementia were excluded (mini-mental state score less than 24). In
all cases, the patients anti-PD medication remained unchanged during
testing, and was converted to a Levodopa Equivalent Dose (LED) using a
standard approach (Tomlinson et al., 2010). The two patient groups did
not significantly differ in the LED they received (p = .572). Before
scanning, each of the participants underwent a general interview and
clinical assessment using the Positive and Negative Symptom Scale
(PANSS) (Kay et al., 1987), and the Global Assessment of Functioning
(GAF) (Hall, 1995). The Apathy Evaluation Scale (AES) (Marin et al.,
1991) was used to assess apathy. The Beck Depression Inventory (BDI)
(Beck et al., 1996) was used to assess depressive symptoms during the
last two weeks and IQ was estimated using the Culture Fair Intelligence
Test (Cattell and Cattell, 1973) and cognitive function was measured
using the mini-mental state examination (Folstein et al., 1975). Fur-
thermore, all participants received a detailed clinical assessment from
an experienced psychiatric nurse, including medical history and an in-
house structured assessment of drug and alcohol intake, which could
lead to further assessment for dependence if indicate.
All subjects had normal or corrected-to-normal visual acuity and
were without any contraindications for MRI scanning. At the time of the
study, none of the participants were taking antipsychotic medications
or had drug or alcohol dependence. The study was approved by the
Cambridgeshire 3 National Health Service research ethics committee.
All subjects gave written informed consent in accordance with the
Declaration of Helsinki.
2.2. Salience oddball task
We used a visual oddball paradigm (Bunzeck et al., 2007) (Fig. 1) in
order to investigate negative emotional salience (see (Bunzeck and
Düzel, 2006; Knolle et al., 2018) for depiction of paradigm). A detailed
description of the paradigm can be found in our previous work (Knolle
et al., 2018): in summary, participants saw a series of greyscale images
of faces and outdoor scenes. 66.6% of these were ‘standard’, neutral
images. Then four types of deviating images were randomly intermixed
with these; each type occurred with a probability of 8.3%. These de-
viant events were: stimuli that evoked a negative emotional response
(‘emotional oddball’, angry face or image of car crash); neutral stimuli
that required a motor response (‘target oddball’); neutral stimuli that
presented a novel image every time they appeared (‘novel oddball’);
and neutral stimuli of the same face or scene that did not require a
motor response or contained negative/positive emotional valence
(‘neutral oddball’). All participants completed 3 runs of 240 trials each
(160 standard trials, and 20 oddball trials each of target, neutral,
emotional and novel stimuli), resulting in a total of 720 trials. The task
contained 50% faces and 50% outdoor scenes, to avoid category-spe-
cific habituation and to make stimulus exploration generalisable to
different visual stimuli. The category switched once per run. The order
in which the visual categories occurred was counterbalanced across
participants. Participants were introduced to the target stimulus prior
to the experimental session for 4.5 s, and they were required to make a
simple button press in response using their left or right index finger to
each of its subsequent appearances during the experiment within the
fMRI-scanner. Participants used their preferred or less affected hand to
press the buttons on the button box for the target picture. No motor
responses were associated with any of the other stimulus types.
During the fMRI-experiment, the pictures were presented for 500 ms
followed by a white fixation cross on a grey background (grey
value = 127) using an inter-stimulus interval (ISI) of 2.7 s. ISI was
jittered with ± 300 ms (uniformly distributed). All of the stimuli were
taken from Bunzeck and Düzel (Bunzeck and Düzel, 2006). The scalp
Table 1
Demographics and pathology of psychiatric aspects of Parkinson’s Disease.
Characteristics Parkinson
Control
Parkinson
Psychosis*
Healthy
Volunteers
Demographics
Participants, n 23 14 17
Age, mean (SD) yr 63.1 (9.4) 62.5 (7.4) 63.1 (SD
9.4)
Gender, % male 60.9 50 42.1
Handeness, % right 87 92.9 89.5
Current employment status
Working (paid), % 30.4 21.4 52.6
Retired, % 60.9 78.6 42.1
Other, % 8.6 – 5.3
Ethnicity
White-british, % 100 100 89.5
Educational qualifications
No qualifications, % 4.3 – 15.8
GSCSEs,BTEC intr.diplom. NVQs
ls1-2, %
13.2 35.7 21.1
A-levels, International
baccalaureate, NVQs lev 3,
BTEC Nationals, %
30.4 14.3 21.1
Higher education, NVQs le 4–5,
HNCs, BTEC professional
diplomas, %
21.7 28.6 31.6
Masters, Doctoral degrees, BTEC
AdvancedProfessional
diplomas, %
30.4 21.4 10.5
Cognition and IQ
MMSE- Total , mean (SD) 29.4 (3.4) 28.0 (1.7) 29.2 (0.8)
Estimated IQ on Test “g” C.Fair,
mean (SD)
90.2 (14.1) 85.8 (17.0) 103.2 (12.0)
Parkinson’s Disease characteristics
Disease duration, mean (SD),yr 9.9 (8.8) 7.7 (5.5) N/A
Hoehn and Yahr stage, % 1/2/3/
4/5
61.5 /26.9
/7.7 /0 /3.8
53.3 /20.0
/26.7 /0 /0
N/A
Levodopa therapy, % yes 80.8 86.7 N/A
Psychopathology
BDI Total score (0–63), mean (SD) 8.1 (4.6) 13.0 (6.9) 3.7 (3.2)
PANSS Total Score (14–98), mean
(SD)
14.1 (0.3) 16.4 (1.5) 14.0 (0.2)
CAARMS group
Attenuated psychosis
(subthresold), n (%)
– 13 (86.7) –
Psychosis threshold, n (%) – 2 (13.3) –
CAARMS score equal or over 3,
global rating scales
UTC –
NBI , n (%) 4 (26.7)
PA , n (%) 12 (80.1)
DS , n (%) 2 (13.3)
ADB –
SS –
GAF Scale-M (1–100), mean (SD) 92.1 (5.9) 81.4 (12.6) 98.0 (2.0)
GAF Scale-Disability (1–90), mean
(SD)
82.0 (6.8) 73.6 (10.5) 89.5 (0.6)
GAF Scalw-Symptoms (1–90),
mean (SD)
82.1 (7.9) 79.8 (11.4) 89.0 (0.6)
Apathy Evaluation Scale (18-
items), mean SD
29.8 (6.7) 35.8 (7.5) –
Comorbidity mental illness
None, % 56.5 57.1 89.5
Depression, % 26.1 21.4 5.3
Anxiety, % 8.7 14.3 5.3
Missing, % 8.7 7.1 –
Family history mental illness (depression)
None (%) 78.3 78.6 84.2
First relatives (%) 8.7 14.3 10.5
Other relatives (%) 8.7 – 5.3
Missing (%) 4.3 7.1 –
* Inclusion criteria: LIFETIME CAARMS scoring equal or over 3 in global and
frequency scales.
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hair and ears of faces were removed artificially; the outdoor scenes did
not include faces. All pictures were grey scaled and normalised to a
mean grey value of 127 (SD 75). The pictures were projected on to the
centre of a screen, and the participants watched them through a mirror
mounted on the head coil, subtending a visual angle of about 8°.
In the current study, we focussed on negative emotional salience,
this contrast was the most robust in terms of generating within and
between group brain activations in our previous study in young adults
with first-episode psychosis (Knolle et al., 2018). We contrasted acti-
vation associated with the emotional and neutral oddball stimuli. Both
types of stimuli have the same frequency. This contrast, therefore, al-
lowed us to examine brain responses to the negative emotional valence
(‘emotional’ vs. ‘neutral’) of a salient event. In contrast, the classical
oddball effect was sought by looking at the contrast between the neutral
oddball and standard stimuli, which is based on frequency differences.
2.3. Behaviour analysis
An analysis of variance (ANOVA) was used to investigate group
differences in responses to the target stimuli (i.e. button presses) as well
as reaction times. Behavioural data were analysed using SPSS 21 (IBM
Corp.).
2.4. Neuroimaging acquisition and analysis protocol
Data was collected using a Siemens Magnetom Trio Tim syngo MR
B17 operating at 3 T.
We used a previously described protocol for the acquisition of the
functional imaging data (Knolle et al., 2018). We acquired gradient-
echo echo-planar T2*-weighted images depicting BOLD contrast from
27 non-contiguous oblique axial plane slices to minimise signal drop-
out in the ventral regions. Images of the whole-brain were not always
retrieved, depending on head size; the superior posterior part of the
cortex was not always imaged (see Supplementary Fig. 1, for examples
of registration). We used the following setup: relaxation time (TR):
1620 ms; echo time (TE): 30 ms; flip angle (FA): 65°; in-plane resolu-
tion: 3 × 3 mm; matrix size: 64 × 64; field of view (FoV):
192 × 192 mm; and bandwidth: 2442 Hz/px. We acquired a total of
437 volumes per participant (27 slices each of 3 mm thickness, inter-
slice gap 1.5 mm). The first five volumes were discarded to allow for T1
equilibration effects.
We used FSL software (FMRIB’s Software Library, www.fmrib.ox.ac.
uk/fsl) version five to analyse the functional data. Participants’ data
(first-level analysis) were processed using the FMRI Expert Analysis
Tool (FEAT). For each subject all three experimental runs were pre-
processed separately using the following procedure: Functional images
were realigned, motion corrected (MCFLIRT (Jenkinson et al., 2002))
and spatially smoothed with a 8 mm full-width half-maximum Gaussian
kernel. A high-pass filter was applied (120 s cut-off). All images were
registered to the whole-brain echo-planar image (EPI) (i.e., functional
image with the whole-brain field of view; sequence parameters: number
of volumes: 3; number of slices: 40 with a slice thickness of 3 mm and
an interslice gap of 1.5 mm; order: interleaved, descending; TR:
2380 ms, TE: 30 ms, FA: 65°, matrix size: 64 × 64; FoV:
192 × 192 mm; in-plane resolution: 3x3 mm), and then to the struc-
tural image of the corresponding participant (MPRAGE; sequence
parameters: TR: 2300 ms, TE: 2.98 ms, flip angle: 9°, spatial resolution:
1 × 1 × 1 mm) and normalised to an MNI template, using linear re-
gistration with FSL FLIRT.
The five explanatory variables (EVs) that we used were the onset
times of the standard, target, emotional, novel and neutral pictures.
They were modelled as 1 s events and convolved with a canonical
double-gamma response function. We added a temporal derivative to
the model to take into account possible variations in the haemodynamic
response function. To capture residual movement-related artefacts, six
covariates were used as regressors of no interest (three rigid-body
translations and three rotations resulting from realignment). We used
four contrasts: target-neutral, emotion-neutral, novel-neutral, and
neutral-standard, although the last contrast represents a frequency
contrast on neutral images. However, as pointed out before, in this
study we focussed on the contrast of emotional-neutral, and report re-
sults on the other contrasts for completeness only. In the “second-level”
within-subject analysis, we combined the data for the three experi-
mental runs for each participant using FEAT with Fixed Effects. This
step was specifically done to average the three experimental runs for
each participants. In the third-level (group) analysis, we conducted an
ANOVA using FEAT, mixed effects (FLAME (FMRIB's Local Analysis of
Mixed Effects) modelling and estimation, a two-stage process using
Bayesian modelling and estimation), on our contrast of interest (nega-
tive emotional oddball vs. neutral oddball)). We used cluster-based
statistical approaches (TFCE) with family wise error corrections.
2.5. Region of interest analysis for all voxels within one cluster
For our main analysis, we pursued a ROI approach: For our salience
type of interest – negative emotional salience – our primary hypothesis
involved four regions of interest that have been found to be most active
in this paradigm (Knolle et al., 2018). These four regions included the
Fig. 1. Task design (displayed for face sti-
muli only). During this visual oddball para-
digm, participants are presented with a
random series of greyscale images of faces
and outdoor scenes. 66.6% of these were
‘standard’ images. The remaining 33.4%
consisted of four types of rare or con-
textually deviant events, which were ran-
domly intermixed with the standard stimuli;
each occurred with a probability of 8.3%.
These deviant events were: neutral stimuli
that required a motor response (‘target
oddball’); stimuli that evoked a negative
emotional response (‘emotional oddball’,
angry face or image of car crash); novel
stimuli (‘novel oddball’, different neutral
images that appear only once); and neutral
stimuli (‘neutral oddball’, neutral image of
face or scene). In the current study, we were
only interested in the contrast between ne-
gative emotional and neutral oddball sti-
muli.
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dopaminergic midbrain (substantia nigra/ventral tegmental area
(VTA)), the ventral and dorsal striatum, the hippocampus and amyg-
dala bilaterally. The mask for the dopaminergic midbrain region was
generated using the probabilistic atlas of Murty and colleagues (Murty
et al., 2014) and has been used successfully in our own previous work
(Ermakova et al., 2018; Knolle et al., 2018). Masks for all other regions
were anatomically derived using the Harvard-Oxford subcortical
structural atlas supplied with FSL. We defined the dorsal and ventral
striatum as a combination of what is in the Harvard-Oxford subcortical
atlas labelled as caudate, putamen and nucleus accumbens. The in-
dividual regions contained voxel sizes as follows: bilateral striatum
(3039 voxels), hippocampus (1033 voxels), amygdala (505 voxels), and
substantia nigra/VTA (645 voxels). See Fig. 2 for display of ROI. For
planned group comparisons, we extracted contrast values (contrast of
parameter estimates, or COPEs in FSL) for each individual from all the
voxels within each of the four ROIs. We furthermore used the Featquery
application in FSL to extract parameter estimates for individual event
types within regions of interest for analysis presented in the supple-
mentary materials. Average COPE values per region of interest were
entered into a multivariate analysis of variance to compare groups.
For completeness and to match the analyses performed in our pre-
vious work using the same paradigm (Knolle et al., 2018) we conducted
additional permutation analyses on the ROI and whole brain. Analysis
steps and results are presented in the supplementary materials.
2.6. Resting cerebral blood flow
Interpretation of BOLD activation effects is complicated by diffi-
culties in assessing whether any results are truly due to differences in
evoked activation, or to baseline cerebral blood flow (CBF) (perfusion)
differences “at rest” (Fleisher et al., 2009; Simon and Buxton, 2015).
CBF could be altered by disease course or medication, as dopaminergic
drugs act directly on the blood vessels and lead to vasodilation which
increases CBF (Leenders et al., 1985). We therefore assessed resting CBF
at baseline for all participants except for one PD patient without psy-
chotic symptoms. For this assessment, we used a continuous arterial
spin labelling (cASL) protocol described in Wang and colleagues (Wang
et al., 2005) and adopted in other studies (Viviani et al., 2009). We used
the following setup: relaxation time: 4000 ms; echo time: 17 ms;
sequence: gradient-echo echo-planar imaging sequence with anterior-
to-posterior phase encoding; multi-slice mode: interleaved; number of
images: 120 with and without labelling; flip angle: 90°; in-plane re-
solution: 3.8 × 3.8 × 6 mm; slice thickness: 6 mm; matrix size:
64 × 64; field of view: 249 × 249 mm; and bandwidth: 2442 Hz/px.
We inserted a 1 s delay between labelling pulse and image acquisition.
We used the SPM2 package (Wellcome Department of Cognitive Neu-
rology, London; online at http://www.fil.ion.ucl.ac.uk) for realignment
and stereotactic normalization to an EPI template (Montreal Neurolo-
gical Institute, resampling size: 2 × 2 × 2 mm). Using the Per-
f_resconstruct_V02 SPM add-on software by Rao and Wang (Department
of Radiology and Center for Functional Neuroimaging at University of
Pennsylvania; online at http://www.cfn.upenn.edu/perfusion/
software.htm), we reconstructed resting CBF values. We then used a
‘simple subtraction’ method (Wang et al., 2003). All volumes were
smoothed using an isotropic Gaussian kernel of full width half-max-
imum (FWHM) of 8 mm prior to the analysis. We used the SPM PET
basic models setup to generate our group statistics and then a one-way
ANOVA with an explicit mask and an ANOVA normalisation. The sig-
nificance threshold was set at p=.05, which was corrected for multiple
comparisons by using the false discovery rate. We also used the Marsbar
toolbox to extract mean CBF for our regions of interest and then em-
ployed those values as covariates in our planned group comparisons for
the task activations. Statistical analyses were generated using SPSS 21
(IBM Corp.).
2.7. Exploratory correlation analysis of symptom scores, brain responses
and medication
We conducted exploratory two-way Pearson correlations per group
between medication (LED), symptom scores (BDI, GAF, AES, CAARMS
total) and brain activations (resting CBF and BOLD responses to four
regions of interest).
2.8. Movement differences during fMRI scan
The task was split into 3 runs of 11.5 min. Runs in which movement
exceeded 3 mm on average or 10 mm maximum were excluded from
the analysis. We only included participants with at least two runs. We
Fig. 2. Display of masks used for the region of interest analysis: the bilateral striatum (blue, 3039 voxels), the hippocampus (red, 1033 voxels), the amygdala (green,
505 voxels), and the substantia nigra/VTA (yellow, 645 voxels). (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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identified two PD patients without psychotic symptoms that had
movement exclusion criterion in two out of three runs and so they were
excluded from all the analyses.
We compared the maximum and mean movement across the three
runs in two separate repeated measure ANOVAs (Table 2). We did not
find any significant group, run or interactions effect, neither for mean
movement nor for maximum movement (all p > 0.1).
3. Results
3.1. Behavioural results
Throughout the task, participants were asked to press a button in
response to two target pictures - one for the face stimuli and one for the
scene stimuli. This ensured that participants maintained their attention
throughout the task. In two separate repeated measure ANOVAs, we
analysed the number of button presses and the reaction times in re-
sponse to both target pictures together (Supplementary Fig. 2A/B and
3, respectively). We found a significant effect for the number of misses
across runs (F(2) = 3.82p = .025, 68.3%power), but no group effect or
interaction. Bonferroni corrected post hoc-tests revealed that partici-
pants missed marginally more button presses in the third compared to
the second run (p = .059). On average, participants failed to press the
button on 6 target trials per run (mean run 1 = 5.78 (SD = 2.4); mean
run 2 = 5.45 (SD = 2.4); mean run 3 = 6.4 (SD = 3.1)). Furthermore,
we found a significant effect for reaction time across runs (F
(2) = 6.31p = .003, 88.9%power), but no group effect or interaction.
Bonferroni corrected post hoc-tests revealed that participants reacted
significantly faster to target images in run 1 compared to run 2
(p = .014) and run 3 (p = .019). On average, participants required
between 500 and 600 ms (mean run1 = 0.531 (SD = 0.1); mean
run2 = 0.555 (SD = 0.1); mean run3 = 0.560 (SD = 0.1)) to make a
response, which is consistent with previous our findings (Knolle et al.,
2018).
3.2. Imaging results
3.2.1. Group analysis of resting cerebral blood flow
The one-way ANOVA on resting CBF data did not reveal any sig-
nificant group differences.
3.2.2. fMRI activation to emotional salience
In our main analysis, we investigated potential group differences in
emotional salience related activation, while controlling for resting CBF.
We extracted the mean BOLD activation (COPE, contrast of parameter
estimates between neutral and emotional oddballs) as well as the mean
resting CBF from each individual region used in the ROI cluster. We
conducted a multivariate analysis of variance to determine whether
there were any statistically significant differences between the
Parkinson’s patients with psychotic symptoms, Parkinson’s patients
without psychotic symptoms and healthy controls on the BOLD acti-
vation per region controlling for CBF in the corresponding region
(Fig. 3).
The multivariate test revealed a significant group effect on brain
activation in response to negative emotional salience within the ROIs,
controlling for resting CBF in ROIs respectively, Pillai’s V = 0.32, F
(8,88) = 2.08p = .046. Tests of between-subject effects furthermore
revealed significant group effects in the amygdala signal bilaterally, F
(2,46) = 5.83p = .006, partial η2 = 0.20, 85.0% power, the hippo-
campus bilaterally, F(2,46) = 3.31p = .016, partial η2 = 0.16, 74.2%
power, the striatum, F(2,46) = 5.17p = .009, partial η2 = 0.18, 80.2%
power, and the substantia nigra/VTA, F(2,46) = 3.52p = .009, partial
η2 = 0.13, 62.8% power. As a control analysis, we ran the multivariate
analysis without controlling for CBF. These results (presented in the
supplementary materials) are very similar and supports the conclusion
that the effects seen were are not driven by differences in the CBF.
In the amygdala, we found bilaterally significantly greater
(p = .001) activation in PD patients with psychotic symptoms (mean1:
29.38, SE 9.2) compared to those without psychotic symptoms (mean1:
−10.52, SE 7.3). Controls (mean1: 6.61, SE 8.6) differed marginally
from PD patients with psychotic symptoms (p = .094), but not from
those without psychotic symptoms.
We found significantly greater activation in the hippocampus bi-
laterally (p = .007) in PD patients with psychotic symptoms (mean1:
19.41, SE 9.0) compared to those without (mean: −12.60, SE 7.1).
Controls (mean1: 10.39, SE 8.5) had marginally significantly greater
activity compared to PD patients without psychotic symptoms
(p = .052) but they did not significantly differ from PD patients with
psychotic symptoms.
In the striatum we found significantly greater (p = .003) activation
in PD patients with psychotic symptoms (mean1: 35.71, SE 14.0)
compared to those without (mean1:−20.39, SE 11.0). Controls (mean1:
16.79, SE 13.3) differed significantly from those patients without psy-
chotic symptoms (p = .044) but not from those with psychotic symp-
toms.
In the substantia nigra/VTA we found significantly greater
(p = .026) activation in PD patients with psychotic symptoms (mean1:
16.66, SE 8.0) compared to those without (mean1: −6.63, SE 6.3).
Controls (mean1: 14.34, SE 7.5) differed significantly from those pa-
tients without psychotic symptoms (p = .045) but not from those with
psychotic symptoms.
3.3. fMRI activation to novelty salience
For completeness, we conducted the same analysis as reported for
emotional salience in novelty, as it is of theoretical interest in models of
psychosis. We did not find any significant results, neither within nor
between groups. We did not analyse for targetness as the participants
did not respond to the target image in roughly 20% of the events and
similarly for rareness as this is a simple frequency response without
specific salient content.
3.4. Results for exploratory correlations of symptom scores, brain responses
and medication
All significant results from the Pearson’s correlations are presented
in Fig. 4. Importantly, in PD patients with psychotic symptoms, we
found a positive correlation between LED and the BOLD activation in
the ROIs (bilateral amygdala: r = 0.603, p = .023, bilateral hippo-
campus: r = 0.560, p = .037, substantia nigra/VTA: r = 0.631,
p = .016, striatum (marginally significant): r = 0.514, p = .060). We
did not find the same correlation in patients without psychotic symp-
toms. Furthermore, in patients with psychotic symptoms, LED was po-
sitively correlated to BDI score (r = 0.591, p = .025) and apathy score
Table 2
Mean and maximum movement across testing blocks and groups (in mm).
Group Mean (SD) Max (SD)
Run 1 PD-Psychosis 0.79 (0.63) 2.22 (1.58)
PD + Psychosis 0.74 (0.40) 2.08 (1.31)
Controls 0.46 (0.24) 1.27 (0.82)
Run 2 PD-Psychosis 0.73 (0.63) 2.21 (1.87)
PD + Psychosis 0.80 (0.54) 1.98 (1.24)
Controls 0.54 (0.43) 1.60 (1.45)
Run 3 PD-Psychosis 0.86 (0.64) 2.70 (2.02)
PD + Psychosis 0.68 (0.51) 2.01 (1.48)
Controls 0.68 (0.83) 1.68 (1.56)
PD-Psychosis: PD patients without psychosis, PD + Psychosis: PD patients with
psychosis.
1 All mean values adjusted for CBF.
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(AES, r = 0.849, p = .004). In the same patients, we found, however,
that the BDI score was positively correlated to resting CBF bilaterally in
the hippocampus (r = 0.631, p = .015), the amygdala (marginally
significant: r = 0.515, p = .059) as well as the substantia nigra
(r = 0.646, p = .013). Furthermore, we did not find any significant
correlations between symptom scores (AES, GAF disability and BDI
scores) and BOLD responses to negative emotional stimuli, except for
one significant positive correlation in the patients with psychotic
symptoms, where higher apathy scores were related to greater BOLD
scores in the striatum (r = 0.695, p = .038). We did not find any
significant correlations between LED and resting CBF.
Pearson correlation analysis did not reveal any significant correla-
tions between BOLD activation and resting CBF in the patient groups. In
the controls however, we found significant correlation between the
BOLD signal in the striatum and resting CBF in the striatum, (r = 0.554,
p = .021), hippocampus (r = 0.526, p = .030) and substantia nigra/
VTA (marginal effect r = 0.458, p = .060).
In order to compare the correlations within each group against each
other, we used the Fisher r-to-z transformation. This allows us to test
whether the correlations in PD patients with psychotic symptoms were
significantly different from the correlations in the other groups (see
Supplementary Table 1). We found that the correlations of LED and
BOLD activation as well as symptom scores were significantly different
between the two patient groups. Correlations between BDI and resting
CBF in patients with psychotic symptoms differed significantly from
those in controls, but not from the other patient group.
4. Discussion
In the current study we investigated negative emotional salience in
PD patients with and without psychotic symptoms and compared them
to healthy controls. Based on previous studies and the literature
(Ermakova et al., 2018; Garofalo et al., 2017; Knolle et al., 2018), we
hypothesised there would be altered brain activity in the striatum,
dopaminergic midbrain (i.e., substantia nigra/VTA), hippocampus and
amygdala in both patients’ groups compared to control subjects, with
an intermediate alteration in PD patients without psychotic symptoms.
The study was not designed to differentiate between emotional scene
and emotional face salience, it is possible that the group differences
were mainly driven by one of these categories. However, as we were
interested in emotional salience processing in general we analyse the
two categories jointly, and ignored their individual contribution to the
effect.
In line with our hypothesis, we found significant differences be-
tween the patient groups. PD patients with psychotic symptoms had
strongly enhanced brain responses in all four regions of interest (i.e.,
the striatum, the substantia nigra/VTA, the hippocampus and the
amygdala) compared to PD patients without psychotic symptoms. PD
patients with psychotic symptoms showed slightly stronger, but insig-
nificantly different BOLD signals compared to controls in all regions bar
the substantia nigra/VTA, suggesting maintained emotional salience
processing in the patients with psychotic symptoms. PD patients
without psychotic symptoms, however, differed significantly (or at least
marginally) from controls in all four regions, showing a generally al-
tered ability to process emotionally salient stimuli. The finding of ab-
normal salience associated brain activation in PD patients without
psychotic symptoms matches the findings in the literature regarding the
deficiencies in emotional processing in PD patients (Moonen et al.,
2017; Péron et al., 2012). Salience associated brain activation in PD
psychosis may appear to be normal when compared to controls, but
when compared to PD patients without psychosis there is a clear dif-
ference, PD psychosis appears to be associated with a relative increase
in salience-associated brain activation. Here we provide a speculative
explanation for these complex but very interesting results.
The finding that PD patients without psychosis show an altered
ability to process emotionally salient stimuli is in concert with the lit-
erature reporting deficiencies in emotional processing in PD patients
(without psychotic symptoms) using ERP and behavioural tasks (for
review see (Moonen et al., 2017; Péron et al., 2012)). The PD patients
with psychotic symptoms show, despite the general deficits in emo-
tional processing inherent to the disorder, a pattern of activation which
is comparable to that of controls. These results might suggest that PD
patients with psychosis show aberrantly enhanced or altered salience
processing which overrides the emotional processing deficits and leads
to an apparent compensation of the emotional processing deficits. This
interpretation, however, requires further experimental exploration.
Our study is the first to investigate emotional salience processing in
PD patients with and without psychotic symptoms and controls.
Importantly, our study controls for putative dopaminergic medication
effects on the baseline BOLD signal strength by assessing the resting
Fig. 3. Bar chart shows mean contrast (COPEs, FSL) values extracted from all voxels of each region of interest and significant group effects (values uncorrected for
covariates). Error bars show ± 1 SE. *p < .05. PD-Psychosis: PD patients without psychosis, PD + Psychosis: PD patients with psychosis.
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cerebral blood flow (resting CBF) in all groups. The current study re-
veals that PD patients with psychotic symptoms show a strongly en-
hanced response to salience in the striatum, substantia nigra/VTA,
amygdala and hippocampus compared to PD patients without psychotic
symptoms. The pattern of activation in the PD patients with psychotic
symptoms is opposite to that which has been reported in patients with
primary psychosis (Knolle et al, 2018). Interestingly, however, in this
work we also found that the stronger the psychotic symptoms, the
stronger the activation in response to emotional salience which is in
line with the results in the PD patients with psychotic symptoms. Cor-
respondingly, an exploratory analysis revealed that in PD patients with
psychotic symptoms, the dose of dopaminergic medication as measured
by LED, positively correlated with the BOLD activation in all ROIs (i.e.,
bilateral amygdala, bilateral hippocampus, substantia nigra/VTA). In
addition, the dopaminergic medication dose was positively linked to
measured depression (BDI) and apathy (AES), as well as negatively
linked to global functioning (GAF disability). In patients without psy-
chotic symptoms, we did not find any significant correlations between
brain activation and psychopathology or medication, with controls also
not showing any correlations between brain activation and psycho-
pathology. There was importantly no significant difference in the
overall medication dose between both patient groups. Our findings do
though support early studies showing that dopaminergic medication is
not the only, or even main, cause of psychotic symptoms in PD, but
might function as an enhancer (for review see (Chang and Fox, 2016;
Gallagher and Schrag, 2012)). We therefore suggest a potential im-
balance in the interaction between medication dependent tonic dopa-
mine levels and phasic dopamine responses to sensory inputs in PD
patients with psychotic symptoms.
Our study indicates a link between the use of dopaminergic medi-
cation, processing alterations of salient stimuli as well as symptom
scores. This is consistent with research showing that the administration
of a dopamine agonist (pramipexole or ropinirole) in young medication-
naïve PD patients led to an increase in aberrant motivational salience
by facilitating arbitrary and illusory associations between stimuli and
rewards, along with faster reaction times to task-irrelevant stimuli as
well as a slight increase in psychotic like symptoms (Nagy et al., 2012).
Further supporting evidence comes from a study by Poletti and col-
leagues (Poletti et al., 2012) which showed that in PD patients delu-
sional jealousy was correlated with use of dopaminergic agonists, but
not with any other medication or dementia. They also reported that
delusional jealousy was independent of visual hallucinations, also as-
sessed in the study, which were correlated with disease duration and
levodopa therapy. The same group showed in a different study (Poletti
et al., 2014) that aberrant salience, as assessed with the Aberrant Sal-
ience Inventory, correlated with dopaminergic treatment, especially
levodopa. This suggests that the dopaminergic restoration of the early
affected dorsal frontostriatal loop might lead to an overdose of the
ventral loop which is relevant for salience processing (Cools et al.,
2001; Poletti et al., 2014). This finding relates to the positive correla-
tion we now report between the daily dose of medication (LED) and the
activation in our ROIs.
In our study, we also found that only in PD patients with psychotic
symptoms did the resting CBF within the four ROIs positively correlate
Fig. 4. Scatter plots show correlations that yielded a significant result in at least
one group. In PD patients with psychotic symptoms, we found a positive cor-
relation between LED and the BOLD activation in the ROIs (A: bilateral
amygdala: r = 0.603, p = .023, B: bilateral hippocampus: r = 0.560, p = .037,
C: substantia nigra/VTA: r = 0.631, p = .016, D: striatum: r = 0.573,
p = .032). LED was positively correlated to BDI score (E: r = 0.591, p = .025)
and apathy score (F: AES, r = 0.849, p = .004); and BDI score was positively
correlated to resting CBF bilaterally in the amygdala (G: marginally significant:
r = 0.515, p = .059), the hippocampus (H: r = 0.631, p = .015) as well as the
substantia nigra (I: r = 0.646, p = .013). In patients without psychotic
symptoms, we found that the BDI score was positively correlated to resting CBF
in the substantia nigra (I: r = 0.450, p = .036). Only in controls we found a
significant correlations between BOLD activation and resting CBF; BOLD signal
in the striatum was significantly correlated to bilateral resting CBF in the hip-
pocampus (J: r = 0.567, p = .018).
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with depression severity, linking higher depression severity with higher
resting CBF. When comparing the correlations across groups, PD pa-
tients with psychotic symptoms were only significantly different from
the correlations in healthy controls. As the correlations were stronger in
patients with, compared to those without psychotic symptoms, the re-
sults provide some additional indication for the mechanistic link be-
tween risk factors like depression and PD psychosis. BOLD signal
strength has been reported to depend on CBF levels (Simon and Buxton,
2015) but importantly we did not find that there were any significant
differences in these parameters between groups. Therefore, it is unlikely
that this correlation could fully explain the opposing signal between the
two patient groups.
Our results are consistent with prior evidence that the use of do-
paminergic medication is linked to the development of psychotic
symptoms in PD patients (Zahodne and Fernandez, 2008). However, we
still lack a full mechanistic explanation of why the use of dopaminergic
drugs lead to psychotic symptoms in some patients but not in others.
The aberrant salience hypothesis of psychosis suggests, first, that a
dysregulated dopaminergic system in the mesolimbic system leads to
the attribution of salience to otherwise irrelevant signals (Kapur, 2003);
and, second, that these irrelevant signals are taken as valid information,
and integrated by seemingly plausible top-down explanations, which
supports the development of delusions and hallucinations.
With regard to the first prerequisite, PD patients show a clear do-
paminergic pathology, which may involve dysregulation in some pa-
tients. Deficits in critical reasoning and accepting hasty cognitive ex-
planations have often been reported in psychosis, mainly in
schizophrenia but also other psychotic disorders (Garety et al., 2005;
Lincoln et al., 2010). ‘Jumping to conclusions’ reflects a bias in critical
reasoning where individuals draw a conclusion based on too little in-
formation for making an informed decision. In psychosis, ‘jumping to
conclusions’ is considered a trait contributing to developing delusions
(Garety and Freeman, 2013), as individuals who jump to conclusions
might be prone to accepting implausible ideas and disregard alternative
explanations. Djamshidan and colleagues were able to detect a bias in
generating and accepting abnormal explanations for aberrantly salient
stimuli in medicated (Djamshidian et al., 2012) and unmedicated (de
Rezende Costa et al., 2016) PD patients. We speculate that this could
relate to a cortical pathology, which is now well recognised to be a
common feature in Parkinson’s disease (Kövari et al., 2003; Mattila
et al., 2000). In the supplement of our current study, we also report
some exploratory ‘jumping to conclusions’ results collected in a reduced
sample from our cohort of patients and controls. The current state of the
data collection does not allow a reliable interpretation, however, it
provides a preliminary indication that PD patients with psychotic
symptoms do show some impairments in this task and present a
jumping to conclusions bias, which was not present in PD patients
without psychotic symptoms or controls. We therefore suggest that the
development of psychotic symptoms in PD patients may result from a
combination of aberrantly enhanced salience signals in the striatal-
hippocampal-midbrain circuits and deficient cognitive reasoning (pos-
sibly cortical) processes. A similar view is presented in Poletti and
Bonuccelli (2013) who argue that impaired salience processing and a
deficit in higher-order control mechanisms (such as the ‘jumping to
conclusions’ bias) potentially giving rise to psychotic symptoms.
In conclusion, our study provides evidence for the first time that
aberrant striatal, hippocampal and amygdala signalling during proces-
sing of non-motivational salient stimuli differentiates PD patients with
and without psychotic symptoms. The results suggest that enhanced
signalling in these regions, possibly leads to the development of psy-
chotic symptoms, in a similar way as that proposed in the ‘aberrant
salience hypothesis’ of psychosis.
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